Acetaminophen (paracetamol) — Competitive Intelligence Brief

Acetaminophen (paracetamol) (Acetaminophen (paracetamol)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Analgesic and antipyretic. Area: Pain Management.

marketed Analgesic and antipyretic Cyclooxygenase (COX), primarily central nervous system isoforms Pain Management Small molecule

Target snapshot

Acetaminophen (paracetamol) (Acetaminophen (paracetamol)) — Hellenic Society of Hematology. Acetaminophen reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Acetaminophen (paracetamol) TARGET	Acetaminophen (paracetamol)	Hellenic Society of Hematology	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Acetaminophen (Ofirmev)	Acetaminophen (Ofirmev)	Brigham and Women's Hospital	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes (central nervous system)
Tylenol Pill	Tylenol Pill	Shanghai Zhongshan Hospital	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Preop acetaminophen IV	Preop acetaminophen IV	AdventHealth	marketed	Analgesic and antipyretic (non-NSAID)	Cyclooxygenase (COX) enzymes
Acetaminophen IV/PO	Acetaminophen IV/PO	The University of Texas Health Science Center, Houston	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes; possibly TRPV1 and other pain pathways
Acetaminophen PO	Acetaminophen PO	The University of Texas Health Science Center, Houston	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Acetaminophen/APAP	Acetaminophen/APAP	John van den Anker	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Analgesic and antipyretic class)

1. Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina · 2 drugs in this class
2. Mallinckrodt · 2 drugs in this class
3. The University of Texas Health Science Center, Houston · 2 drugs in this class
4. Hellenic Society of Hematology · 1 drug in this class
5. John van den Anker · 1 drug in this class
6. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 drug in this class
7. Maoxiang Group Jilin Pharmaceutical Co., Ltd. · 1 drug in this class
8. Merck Sharp & Dohme LLC · 1 drug in this class
9. Mount Sinai Hospital, Canada · 1 drug in this class
10. Nantes University Hospital · 1 drug in this class